Korro Bio, Inc. (KRRO) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US5009461089
Korro Bio, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 6.39 m USD |
| Operating income | -121.86 m USD |
| EBIT | -116.62 m USD |
| Net income | -117.26 m USD |
| Diluted EPS – continuing operations | -12.48 USD |
Full history since 2016, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Korro Bio, Inc.
Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia. It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe drug-associated anesthetics, and other pain indications. Korro Bio, Inc. has a collaboration agreement with Novo Nordisk A/S to treat cardiometabolic diseases. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
More stocks
- Amazing Microelectronic (6411.TWO)
- Galan Lithium Ltd (GLN.AX)
- Young Fast Optoelectronics Co Ltd (3622.TW)
- Finwise Bancorp (FINW)
- CONDUENT Inc (CNDT)
- Limes Schlosskliniken (LIK.DE)
- Shin Yang Shipping Corporation Bhd (5173.KL)
- Teixeira Duarte (TDSA.LS)
- Savior Lifetec (4167.TWO)
- Critical Holdings Berhad (0291.KL)
- Chung Hwa Food Industrial Co Ltd (4205.TWO)
- Acer Cyber Security Inc. (6690.TWO)
Not investment advice. All data without warranty, price as of 11.11.2026. Details in the risk notice.